pentosidine has been researched along with candesartan cilexetil in 1 studies
| Studies (pentosidine) | Trials (pentosidine) | Recent Studies (post-2010) (pentosidine) | Studies (candesartan cilexetil) | Trials (candesartan cilexetil) | Recent Studies (post-2010) (candesartan cilexetil) |
|---|---|---|---|---|---|
| 577 | 34 | 205 | 628 | 151 | 133 |
| Protein | Taxonomy | pentosidine (IC50) | candesartan cilexetil (IC50) |
|---|---|---|---|
| Type-1 angiotensin II receptor | Oryctolagus cuniculus (rabbit) | 0.2 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 2.4547 | |
| DNA polymerase kappa | Homo sapiens (human) | 7.4 | |
| DNA polymerase iota | Homo sapiens (human) | 6.2 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 5 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 0.7244 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuhara, M; Fukui, M; Hasegawa, G; Ikeda, T; Nakamura, N; Obayashi, H; Ohta, M; Oku, H; Okuno, T; Sugiyama, T | 1 |
1 other study(ies) available for pentosidine and candesartan cilexetil
| Article | Year |
|---|---|
Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Arginine; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Drug Evaluation, Preclinical; Electroretinography; Gene Expression Regulation; Glycation End Products, Advanced; Lysine; Male; Rats; Rats, Sprague-Dawley; Retina; Reverse Transcriptase Polymerase Chain Reaction; Tetrazoles; Vascular Endothelial Growth Factor A | 2007 |